Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Clin Pharmacol Ther. 2015 May 2;98(1):25–33. doi: 10.1002/cpt.127

Table 1.

Demographics of PK population patients by dose group

Parameter Lisinopril dose group
All (n=22)
Low dose 0.1 mg/kg (n=12) Middle dose 0.2 mg/kg (n=8) High dose 0.4 mg/kg (n=2)
Age (y) 14.9 ± 2.3 13 ± 3 9.5 ± 3.5 13.8 ± 3.0
Weight (kg) 56.8 ± 19.4 50.2 ± 28.7 23.1 ± 3 51.3 ± 23.8
Female 4 (42%) 2 (25%) 1 (50%) 7 (32%)
Race/ethnicity
 White 7 (58%) 2 (25%) 2 (100%) 11 (50%)
 Black 3 (25%) 4 (50%) 0 7 (32%)
 American Indian or Alaska Native 0 (0) 1 (13%) 0 1 (5%)
 Not reported 2 (17%) 1 (13%) 0 3 (14%)
Ethnicity
 Hispanic/Latino 2 (17%) 2 (25%) 0 4 (18%)
 eGFR at baseline (ml/min per 1.73m2) 72.5 ± 25.7 (29.6, 111.2) 62 ± 16.7 (29.2, 79.8) 89.3 ± 44.4 (57.8, 120.6) 70.2 ± 24.4
 eGFR at PK visit (ml/min per 1.73m2) 73.1 ± 30.7 (36.7, 139.0) 63.2 ± 18.4 (30.3, 86.0) 100.2 ± 56.6 (60.0, 140.2) 72.0 ± 29.4
 Time since transplant (years) 4.8 ± 4.7 4.9 ± 3.4 0.9 ± 0.4 4.5 ± 4.1

Data are mean ± SD (range) or counts (%); PK, pharmacokinetic; eGFR, estimated glomerular filtration rate calculated by modified Schwartz formula (= 0.413 x length [cm]/serum creatinine [mg/dl]).